Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.65 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801745 | 0.92 | CYP2C9 (0.78) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10724135 | 0.92 | CYP2C9 (0.78) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10910419 | 0.89 | CACNA1C (0.54) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10913306 | 0.89 | KMT2A (0.54) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10913461 | 0.89 | KMT2A (0.54) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10924747 | 0.89 | CYP1A2 (0.84) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4797084 | 0.89 | CYP1A2 (0.84) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10913148 | 0.88 | CYP1A2 (0.53) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7446251 | 0.87 | MAPT (0.75) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10912830 | 0.86 | CYP2C9 (0.59) | CYP2C9KMT2ACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111097050-A | Composition comprising fatty acid or derivative thereof and phenylpyridine derivative | 黄泳华 | 2020-05-05 | — | — | CN | claimed |
| EP-0202282-B1 | NEW USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES | SANDOZ AG (CH) | 1992-07-08 | — | — | EP | claimed |
| EP-0094159-B1 | DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-14 | — | — | EP | claimed |
| US-4510150-A | 4-(2,1,3-BENZ-OXA-OR-THIA-DIAZOLYL)-1,4-DIHYDROPYRIDINES AND A BETA-BLOCKER | SANDOZ LTD. (CH) | 1985-04-09 | — | — | US | claimed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| US-11142549-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-10-12 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
| US-5209933-A | A dihydropyridine compound | SYNTEX (U.S.A.) INC. (US) | 1993-05-11 | — | — | US | disclosed |
| US-5198226-A | Sustained release | SYNTEX (U.S.A.) INC. (US) | 1993-03-30 | — | — | US | disclosed |
| US-5064839-A | Vasodilators, coronary disorders, hypotensive | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-11-12 | — | — | US | disclosed |
| US-4994461-A | Vasodilators; treating cardiovascular disorders | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-02-19 | — | — | US | disclosed |
| US-4940556-A | SUSTAINED RELEASE OF CALCIUM CHANNEL BLOCKERS | SYNTEX (U.S.A.) INC. (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
| US-11142549-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | CYP2C9 578/4885KMT2A 4129/4885CYP1A2 1311/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CYP2C9 3101/4885KMT2A 3991/4885CYP1A2 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.